<DOC>
	<DOC>NCT00127049</DOC>
	<brief_summary>This is a prospective multicenter phase II trial of gemcitabine, cisplatin, and ifosfamide (GIP) in patients with relapsed non-seminomatous germ-cell tumors (NSGCT) and a predicted favorable prognosis.</brief_summary>
	<brief_title>Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Patients older than 16 years Histologicallyproven disseminated (non stage I) NSGCT, or diagnosis of NSGCT based on very elevated serum human chorionic gonadotropin (HCG) and/or alpha fetoprotein (AFP) Relapsed disease classified as good prognosis according to the Memorial SloanKettering Cancer Center (MSKCC) classification criteria: Testicular primary site Prior treatment limited to one program (or 6 or fewer cycles of cisplatin) Either a complete response or a partial response with normal serum AFP and HCG Relapse documented by rising AFP and/or HCG or by a biopsy No previous carcinoma, except basalcell carcinoma of the skin Adequate renal function: measured or calculated creatinine clearance&gt; 60 ml/min Absolute granulocyte count &gt;= 1,500/mm3, platelets &gt;= 100,000 mm3, bilirubin &lt; 1.5 fold the upper normal value Signed informed consent. Patients infected by the human immunodeficiency virus (HIV) Patients who do not fit inclusion criteria</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Patients with relapsed non-seminomatous germ-cell tumors (NSGCT)</keyword>
</DOC>